<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03931239</url>
  </required_header>
  <id_info>
    <org_study_id>VABIOTECH-01</org_study_id>
    <nct_id>NCT03931239</nct_id>
  </id_info>
  <brief_title>The Transparent Safety Study of the 5 in 1 (DTwP-rHepB-Hib) Combination Vaccine Produced by the Indian Serine Institute in Children of Viet Nam Healthy From 6 to 12 Weeks of Age in a 3-dose Regimen, the Interval Between Doses is 4 Weeks</brief_title>
  <official_title>An Open Label, Multicentric, Bridging Study to Assess the Safety of Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemophilus Influenzae Type b Conjugate Vaccine (Adsorbed) Manufactured by Serum Institute of India Pvt. Ltd in Vietnamese Infants Aged 6-12 Weeks, Given as a 3-dose Regime, With 4 Week Intervals Between the Doses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vabiotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vietstar Biomedical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vabiotech</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate safety and tolerability of Diphtheria, Tetanus,
      Pertussis, Hepatitis B and Haemophilus influenzae type b Conjugate Vaccine Adsorbed in
      Vietnamese infants aged 6-12 weeks. This is an open label, single group, bridging study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be an open label, single group, bridging study. Study subjects will be vaccinated
      with 3 (three) vaccine doses. The first vaccine will be administered intramuscularly starting
      at 6-12 weeks of age followed by two doses at four-week interval.

      This study was performed in strict accordance with Good Clinical Practice.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Actual">July 30, 2018</completion_date>
  <primary_completion_date type="Actual">June 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Participants With Adverse Events Related to DTPw-HB-Hib vaccine Administration</measure>
    <time_frame>Days 0 to 28 post-vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Adverse Events Related to DTPw-HB-Hib vaccine Administration</measure>
    <time_frame>Baseline to 30 minutes post-vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">222</enrollment>
  <condition>Diphtheria</condition>
  <condition>Tetanus</condition>
  <condition>Pertussis</condition>
  <condition>Hepatitis B</condition>
  <condition>Haemophilus Influenzae Type B</condition>
  <arm_group>
    <arm_group_label>Vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DTPw-HB-Hib vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Study subjects will be vaccinated with 3 (three) vaccine doses. The first vaccine will be administered intramuscularly starting at 6-12 weeks of age followed by two doses at four-week interval</intervention_name>
    <description>An openlabel, multicentric, bridging study to assess the safety of Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemophilus influenzae type b Conjugate Vaccine (Adsorbed) manufactured by Serum Institute of India Pvt. Ltd in Vietnamese infants aged 6-12 weeks, given as a 3-dose regime, with 4 week intervals between the doses</description>
    <arm_group_label>Vaccination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy infants, both sexes, between 6 and 12 weeks of age on the day of screening and
             enrollment

          -  Subject born at full term of pregnancy (greater or equal to 37 weeks) and Birth weight
             ≥2500 grams

          -  Weight ≥ 3,300 grams at the time of screeningSubject with good health as determined by
             the medical history, physical examination and clinical judgment of the Investigator

          -  Parent / legal representative can understand and be able to comply with the
             requirements of the protocol

          -  Subjects born to mothers who are seronegative to HIV, HBV and HCV through a blood test
             or maternity record.

          -  Parent / legal representative is willing to voluntarily sign the consent form for the
             participant

        Exclusion Criteria:

          -  History of diphtheria, tetanus, pertussis, hepatitis B, or Hib infections (confirmed
             either clinically, serologically or microbiologically)

          -  Fever (temperature ≥37.50C) or hypothermia (≤35.50C) or acute illness / infection that
             requires treatment.

          -  Previous vaccination against diphtheria, tetanus, pertussis and Haemophilus influenzae
             type b diseases.

          -  Known allergy to any component of the vaccine;

          -  Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal
             functional abnormality, as determined by physical examination.

          -  Being treated with anticoagulants or at high risk of bleeding.

          -  A family history of SIDS (sudden infant death syndrome)

          -  Have received any blood products, corticosteroids, cytotoxic drugs, immunosuppressive
             therapy, radiation therapy in the last 4 weeks.

          -  Have participated in another clinical trial within 30 days prior to the study
             vaccination or may participate in the course of the study.

          -  A family history of congenital or hereditary immunodeficiency.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine.

          -  Major congenital defects.

          -  History of any neurological disorders or seizures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>12 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hung Yen, Kim Dong</name>
      <address>
        <city>Hung Yen</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 25, 2019</study_first_submitted>
  <study_first_submitted_qc>April 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2019</study_first_posted>
  <last_update_submitted>May 1, 2019</last_update_submitted>
  <last_update_submitted_qc>May 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

